DY
VRDN icon

Dowling & Yahnke’s Viridian Therapeutics VRDN Stock Holding History

Dowling & Yahnke’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-2,666
Closed -$498K – 282
2017
Q1 		$498K Buy
+2,666
New +$460K 0.05% 215

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dowling & Yahnke's VRDN Position: Q2 2017 in Review

Dowling & Yahnke sold out of Viridian Therapeutics (VRDN) in Q2 2017, closing a stake of 2,666 shares — an estimated $498K sold.

Dowling & Yahnke first reported a position in VRDN in Q1 2017 and held it in 1 quarter. The position peaked at $498K in Q1 2017. 31 funds tracked by Wall St. Rank hold VRDN as of Q2 2017.

  • Dowling & Yahnke reported no remaining Viridian Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Dowling & Yahnke sold 2,666 Viridian Therapeutics shares in Q2 2017, an estimated $498K.
  • Dowling & Yahnke first reported a position in Viridian Therapeutics in Q1 2017 and held it in 1 quarter.
  • Dowling & Yahnke's Viridian Therapeutics position peaked at $498K in Q1 2017.
  • 31 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2017.

Based on Dowling & Yahnke's 13F filing for Q2 2017, filed 3 Aug 2017.